Objective: Pilocytic astrocytomas (PAs) are relatively benign tumors, usually enhancing on post-contrast MRI and often characterized by a mural nodule within a cystic component. Surgical resection represents the mainstay of treatment, and extent of resection (EOR) is associated with improved survival. In this study, we analyzed the effect of sodium fluorescein (SF) on the visualization and resection of these circumscribed astrocytic gliomas. Methods: Surgical databases at two neurosurgical departments (Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy and Department of Neurosurgery, University Medical Center Regensburg, Regensburg, Germany) were retrospectively reviewed to identify the cohort of patients with pilocytic astrocytoma who had undergone fluorescein-guided tumor resection at any of the centers between March 2016 and February 2022. SF was intravenously injected (5 mg/kg) immediately after the induction of general anesthesia. Tumors were removed using a microsurgical technique with the YELLOW 560 filter (Carl Zeiss Meditec, Oberkochen, Germany). Results: Forty-four patients (25 males and 19 females; 26 pediatric patients, mean age of 9.77 years, range 2 to 17 years; and 18 adult patients, mean age of 34.39 years, range 18 to 58 years) underwent fluorescein-guided surgery. No side effects related to SF occurred. In all tumors, contrast enhancement on preoperative MRI was correlated with intense, heterogeneous yellow fluorescence with bright fluorescent cystic fluid. Fluorescein was considered helpful in distinguishing tumors from viable tissue in all cases except three patients due to faint fluorescein enhancement. Biopsy was intended in two operations, and partial resection was intended in three operations. Gross total resection was achieved in 24 cases out of 39 patients scheduled for tumor removal (61.54%), in five cases a minimal residual volume was highlighted by postoperative MRI despite the intraoperative subjective evaluation of complete tumor removal (12.82%); in the other 10 cases, the resection was subtotal with fluorescent residual spots to avoid neurological worsening (25.64%). Conclusions: The use of SF is a valuable method for safe fluorescence-guided tumor resection. Our data showed a positive effect of fluorescein-guided surgery on intraoperative visualization during resection of Pas, suggesting a possible role in improving the extent of resection of these lesions.
Objective: Pilocytic astrocytomas (PAs) are relatively benign tumors, usually enhancing on post-contrast MRI and often characterized by a mural nodule within a cystic component. Surgical resection represents the mainstay of treatment, and extent of resection (EOR) is associated with improved survival. In this study, we analyzed the effect of sodium fluorescein (SF) on the visualization and resection of these circumscribed astrocytic gliomas. Methods: Surgical databases at two neurosurgical departments (Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy and Department of Neurosurgery, University Medical Center Regensburg, Regensburg, Germany) were retrospectively reviewed to identify the cohort of patients with pilocytic astrocytoma who had undergone fluorescein-guided tumor resection at any of the centers between March 2016 and February 2022. SF was intravenously injected (5 mg/kg) immediately after the induction of general anesthesia. Tumors were removed using a microsurgical technique with the YELLOW 560 filter (Carl Zeiss Meditec, Oberkochen, Germany). Results: Forty-four patients (25 males and 19 females; 26 pediatric patients, mean age of 9.77 years, range 2 to 17 years; and 18 adult patients, mean age of 34.39 years, range 18 to 58 years) underwent fluorescein-guided surgery. No side effects related to SF occurred. In all tumors, contrast enhancement on preoperative MRI was correlated with intense, heterogeneous yellow fluorescence with bright fluorescent cystic fluid. Fluorescein was considered helpful in distinguishing tumors from viable tissue in all cases except three patients due to faint fluorescein enhancement. Biopsy was intended in two operations, and partial resection was intended in three operations. Gross total resection was achieved in 24 cases out of 39 patients scheduled for tumor removal (61.54%), in five cases a minimal residual volume was highlighted by postoperative MRI despite the intraoperative subjective evaluation of complete tumor removal (12.82%); in the other 10 cases, the resection was subtotal with fluorescent residual spots to avoid neurological worsening (25.64%). Conclusions: The use of SF is a valuable method for safe fluorescence-guided tumor resection. Our data showed a positive effect of fluorescein-guided surgery on intraoperative visualization during resection of Pas, suggesting a possible role in improving the extent of resection of these lesions.
Authors: Roberto Jose Diaz; Roberto Rey Dios; Eyas M Hattab; Kelly Burrell; Patricia Rakopoulos; Nesrin Sabha; Cynthia Hawkins; Gelareh Zadeh; James T Rutka; Aaron A Cohen-Gadol Journal: J Neurosurg Date: 2015-04-03 Impact factor: 5.115
Authors: Gabriela Boschetti; Adrialdo Jose Santos; Kellen Paiva Fermon; Gustavo Lopes de Freitas Honório; Gabriel Batistella; Solena Ziemer Kusma; João Norberto Stávale; Manoel Antonio de Paiva Neto; Suzana Maria Fleury Malheiros Journal: World Neurosurg Date: 2019-09-21 Impact factor: 2.104
Authors: Camilla de Laurentis; Julius Höhne; Claudio Cavallo; Francesco Restelli; Jacopo Falco; Morgan Broggi; Lorenzo Bosio; Ignazio G Vetrano; Marco Schiariti; Costanza M Zattra; Paolo Ferroli; Karl-Michael Schebesch; Francesco Acerbi Journal: J Neurosurg Sci Date: 2019-04-23 Impact factor: 2.279
Authors: C Colin; L Padovani; C Chappé; S Mercurio; D Scavarda; A Loundou; F Frassineti; N André; C Bouvier; A Korshunov; G Lena; D Figarella-Branger Journal: Neuropathol Appl Neurobiol Date: 2013-10 Impact factor: 8.090
Authors: Francesco Acerbi; Claudio Cavallo; Karl-Michael Schebesch; Mehmet Osman Akçakaya; Camilla de Laurentis; Mustafa Kemal Hamamcioglu; Morgan Broggi; Alexander Brawanski; Jacopo Falco; Roberto Cordella; Paolo Ferroli; Talat Kiris; Julius Höhne Journal: World Neurosurg Date: 2017-09-19 Impact factor: 2.104
Authors: Jacopo Falco; Claudio Cavallo; Ignazio G Vetrano; Camilla de Laurentis; Lampros Siozos; Marco Schiariti; Morgan Broggi; Paolo Ferroli; Francesco Acerbi Journal: Front Surg Date: 2019-08-13